First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C. Le Tourneau(Université de Versailles Saint-Quentin-en-Yvelines), Marie Dutreix(Centre National de la Recherche Scientifique), Célèste Lebbé(Inserm), Jean‐Marc Cosset(Institut Curie), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), E. Maubec(Inserm), B Asselain(Institut Curie), Thomas Jouary(Hôpital Saint-André), P. Joly(Inserm), Flavien Devun(HiFiBiO Therapeutics (France)), Pierre Bey(Institut Curie), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Jian‐Sheng Sun(HiFiBiO Therapeutics (France)), Laurent Mortier, L. Thomas(University of Liverpool), M. Marty(Hôpital Saint-Louis), Brigitte Dréno(Nantes Université), Avril Mf(Hôpital Cochin), Youlia Kirova(Institut Curie)
Cited by 35
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k